Quetmolimab（Cat No.:I042195）is a monoclonal antibody that targets the immune checkpoint receptor TIGIT (T-cell immunoreceptor with Ig and ITIM domains), which is expressed on T-cells and other immune cells. TIGIT plays a role in inhibiting immune responses, enabling tumors to evade immune detection. By blocking TIGIT, quetmolimab aims to enhance T-cell activation and restore immune system function, thereby improving the body’s ability to fight cancer. It is being investigated in clinical trials for its potential to treat a range of cancers, including solid tumors, either alone or in combination with other immunotherapies.
